Pharmaceutical composition, pharmaceutical preparation and preparation method of tropisetron hydrochloride oral solution
The combination of totansetron hydrochloride, terpene glycosides and citric acid to adjust pH value is formed, which solves the degradation problem of totansetron hydrochloride under different conditions and achieves its high stability in solution and prolonged shelf life.
Patent Information
- Application Number
- CN202411233001.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-22
AI Technical Summary
The existing oral solution of totanetron hydrochloride is prone to degradation under heat, acid, alkali, oxidation and light conditions, resulting in a decrease in the preparation content and an increase in side effects, and lacks an effective method to improve stability.
A composition of totansetron hydrochloride and terpene glycosides (such as steviol) is used, and the pH value is adjusted to 4.3~5.7 through citric acid and sodium citrate to form a complex to improve stability and inhibit hydrolysis and oxidation reactions.
The stability of totansetron hydrochloride is significantly improved, the content changes slightly during long-term storage, extending the shelf life of the preparation, and is suitable for industrial production through simple preparation methods.
Smart Images

Figure SMS_1
Abstract
Description
Technical Field
[0001] The invention relates to the field of pharmaceutical preparations, in particular to a pharmaceutical composition and a pharmaceutical preparation and a preparation method of a tropisetron hydrochloride oral solution. Background Art
[0002] Chemotherapy is one of the important means of treating cancer patients. Chemotherapy drugs have a positive therapeutic effect and are widely used, but they have many adverse reactions. Among them, chemotherapy-induced nausea and vomiting (CINV) is one of the most serious adverse reactions of chemotherapy, which seriously affects the quality of life of patients and also determines the compliance and efficacy of patients' medication. 5-HT3 receptor blockers are currently the main drugs for the treatment of CINV in China, because they can block the central or peripheral release of 5-HT3 during chemotherapy, so 5-HT3 receptor blockers can effectively stop vomiting. Currently, the common ones include ondansetron, granisetron, tropisetron, ramosetron, azasetron, palonosetron, etc.
[0003] Tropisetron is characterized by its highly selective antagonism of 5-HT3 receptors in peripheral nerves and central nervous system, and can double block the chemical transmission in the vomiting reflex, blocking the presynaptic 5-HT receptor excitation of peripheral neurons in the vomiting reflex center, and directly affecting the effect of the vagus nerve afferent area transmitted by 5-HT3 receptors in the central nervous system. It is highly effective in preventing vomiting caused by cancer chemotherapy. The advantage of tropisetron is that the dose is linear, while there is no statistically significant difference in the dose and efficacy of ondansetron, granisetron, and azasetron after exceeding a certain dose.
[0004] The main clinical effect of Tropisetron Hydrochloride is to prevent malignant vomiting caused by surgery and treat gastrointestinal discomfort symptoms after chemotherapy and radiotherapy in cancer patients. It can relieve gastrointestinal flatulence, protect gastrointestinal mucosa, relieve patients' pain, and reduce the side effects of chemotherapy and radiotherapy. Oral administration is generally taken 1-2 hours before chemotherapy and radiotherapy.
[0005] During long-term storage, the existing tropisetron hydrochloride oral solution on the market will degrade to varying degrees under heat, acid, alkali, oxidation and light conditions, resulting in a decrease in the content of the preparation, an increase in related substances and a darker color. The main reason is that tropisetron hydrochloride is an indolecarboxylic acid derivative, and the degradation products include indole-3-carboxylic acid, indole-3-carboxaldehyde, a-tropinol, β-isomer, etc. The stability of this product is related to its structure. It has better stability when the pH is between 4.3 and 5.7. Low or high pH can affect the degradation rate of the product. There is currently no good way to slow down its degradation. Summary of the invention
[0006] In view of this, the technical problem to be solved by the present invention is to provide a pharmaceutical composition, a pharmaceutical preparation and a preparation method of an oral solution of tropisetron hydrochloride. The pharmaceutical composition provided by the present invention has high stability of tropisetron hydrochloride and basically will not be degraded during long-term storage.
[0007] The present invention provides a pharmaceutical composition comprising:
[0008] Tropisetron hydrochloride;
[0009] and terpene glycosides.
[0010] The tropisetron hydrochloride of the present invention is used as a pharmaceutical active ingredient in the pharmaceutical composition of the present invention. The terpene glycosides of the present invention are specifically selected from one or more of tetracyclic diterpene glycosides. More specifically, the terpene glycosides are selected from one or more of mogroside, paeoniflorin and stevioside, and are most preferably selected from stevioside (Steviol Glycosides, STE-G). The mass ratio of tropisetron hydrochloride and terpene glycosides of the present invention is 1: (0.8~1.2), preferably 1: 0.9. In the pharmaceutical composition of the present invention, the terpene glycosides not only play the role of flavor corrective, but more importantly, play the role of stabilizer. The glycosidic bond in its structure can effectively inhibit the hydrolysis of tropine alcohol esters and improve its stability in water. In the present invention, the terpene glycosides form a complex with tropisetron hydrochloride, which greatly improves the stability of tropisetron hydrochloride in solution.
[0011] The pharmaceutical composition of the present invention further comprises citric acid and sodium citrate; the citric acid and sodium citrate are used as pH regulators in the pharmaceutical composition of the present invention to adjust the pH to 4.3-5.7, especially to 4.5-5.5, which can inhibit the hydrolysis and oxidation of the main drug and further improve the stability of the main drug. The mass ratio of tropisetron hydrochloride, terpene glycosides, citric acid and sodium citrate of the present invention is 1: (0.8-1.2): 0.4: 0.7, preferably 1: 0.9: 0.4: 0.7
[0012] The present invention also provides a pharmaceutical preparation, which comprises the pharmaceutical composition described in any of the above technical solutions and a pharmaceutically acceptable additive. In certain embodiments of the present invention, the dosage form of the pharmaceutical preparation is an oral solution, an injection or a tablet. In certain embodiments of the present invention, the pharmaceutically acceptable additive is selected from at least one of a flavoring agent, a pH regulator, a thickener, an antibacterial agent, a preservative and a solubilizer.
[0013] The present invention also provides a method for preparing a tropisetron hydrochloride oral solution, comprising the following steps: mixing the pharmaceutical composition described in any of the above technical solutions in a solvent, adjusting the pH value to 4.3-5.7, preferably adjusting the pH value to 4.5-5.5, to obtain a tropisetron hydrochloride oral solution.
[0014] Specifically, the preparation method of the present invention comprises the following steps: mixing citric acid, sodium citrate, glycerol and water, cooling to below 35°C, then adding tropisetron hydrochloride and terpene glycosides thereto, adjusting the pH value, and obtaining a tropisetron hydrochloride oral solution.
[0015] More specifically, the preparation method of the present invention further comprises filtering and filling the obtained solution after adjusting the pH value to obtain a tropisetron hydrochloride oral solution. In one embodiment of the present invention, the filtration is specifically filtering through 0.45 μm and 0.22 μm PES filter cartridges. In one embodiment of the present invention, the filling volume is 10 mL, and a 10 mL soda-lime glass tube oral solution bottle is used for the filling, and the tropisetron hydrochloride content in the obtained tropisetron hydrochloride oral solution is 5 mg. In one embodiment of the present invention, the liquid density of the obtained tropisetron hydrochloride oral solution is 1.002~1.009 kg / L.
[0016] The present invention provides a pharmaceutical composition, a pharmaceutical preparation and a method for preparing an oral solution of tropisetron hydrochloride. The pharmaceutical composition provided by the present invention comprises: tropisetron hydrochloride and terpene glycosides. The terpene glycosides described in the present application can form a complex with tropisetron hydrochloride, greatly improving the stability of tropisetron hydrochloride in solution; by controlling the weight ratio and pH value of the two, the stability of tropisetron hydrochloride can be further improved. Experiments show that the oral solution of tropisetron hydrochloride provided by the present invention is stable in content within 6 months of accelerated testing and even within 24 months of long-term testing, and the change of related substances is small, which prolongs the storage period of the preparation; at the same time, the preparation method provided by the present invention has a simple process and is suitable for industrial production. DETAILED DESCRIPTION
[0017] The present invention discloses a method for preparing a pharmaceutical composition, a pharmaceutical preparation and a tropisetron hydrochloride oral solution. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described by preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.
[0018] The present invention will be further described below in conjunction with embodiments:
[0019] Example 1
[0020] Tropisetron hydrochloride 225.6 g, glycerol 50 g, stevioside 200 g, citric acid 80 g, sodium citrate 160 g and purified water in appropriate amounts are prepared according to the following method:
[0021] (1) Add citric acid, sodium citrate and glycerol to 300 L of purified water, stir to dissolve, and cool to below 35°C;
[0022] (2) adding tropisetron hydrochloride to the solution obtained in step (1), then adding stevioside and stirring to dissolve, diluting the volume to 400 L, and adjusting the pH value to 5.0 with citric acid and sodium citrate;
[0023] (3) After filtering through 0.45 μm and 0.22 μm PES filter cartridges, the solution was bottled to obtain a tropisetron hydrochloride oral solution with a density of 1.005 kg / L.
[0024] Example 2
[0025] Tropisetron hydrochloride 225.6 g, stevioside 225 g, citric acid 80 g, sodium citrate 160 g and purified water in appropriate amounts are prepared according to the following method:
[0026] (1) Add citric acid, sodium citrate and glycerol to 300 L of purified water, stir to dissolve, and cool to below 35°C;
[0027] (2) adding tropisetron hydrochloride to the solution obtained in step (1), then adding stevioside and stirring to dissolve, diluting the volume to 400 L, and adjusting the pH value to 5.1 with citric acid and sodium citrate;
[0028] (3) After filtering through 0.45 μm and 0.22 μm PES filter cartridges, the solution was bottled to obtain a tropisetron hydrochloride oral solution with a density of 1.002 kg / L.
[0029] Example 3
[0030] Tropisetron hydrochloride 225.6 g, glycerol 50 g, stevioside 181 g, citric acid 80 g, sodium citrate 160 g and purified water in appropriate amounts are prepared according to the following method:
[0031] (1) Add citric acid, sodium citrate and glycerol to 300 L of purified water, stir to dissolve, and cool to below 35°C;
[0032] (2) adding tropisetron hydrochloride to the solution obtained in step (1), then adding stevioside and stirring to dissolve, diluting the volume to 400 L, and adjusting the pH value to 4.4 with citric acid and sodium citrate;
[0033] (3) After filtering through 0.45 μm and 0.22 μm PES filter cartridges, the solution was bottled to obtain a tropisetron hydrochloride oral solution with a density of 1.009 kg / L.
[0034] Example 4
[0035] Tropisetron hydrochloride 225.6 g, stevioside 270 g, citrate 80 g, sodium citrate 160 g and purified water in appropriate amounts are prepared according to the following method:
[0036] (1) Add citric acid, sodium citrate and glycerol to 300 L of purified water, stir to dissolve, and cool to below 35°C;
[0037] (2) adding tropisetron hydrochloride to the solution obtained in step (1), then adding stevioside and stirring to dissolve, diluting the volume to 400 L, and adjusting the pH value to 5.3 with citric acid and sodium citrate;
[0038] (3) After filtering through 0.45 μm and 0.22 μm PES filter cartridges, the solution was bottled to obtain a tropisetron hydrochloride oral solution with a density of 1.008 kg / L.
[0039] Comparative Example 1
[0040] Tropisetron hydrochloride 225.6 g, citric acid 80 g, sodium citrate 160 g and purified water in appropriate amounts were prepared according to the following method:
[0041] (1) Add citric acid, sodium citrate and glycerol to 300 L of purified water, stir to dissolve, and cool to below 35°C;
[0042] (2) adding tropisetron hydrochloride to the solution obtained in step (1) and stirring to dissolve, diluting the volume to 400 L, and adjusting the pH value to 5.0 with citric acid and sodium citrate;
[0043] (3) After filtering through 0.45 μm and 0.22 μm PES filter cartridges, the solution was bottled to obtain a tropisetron hydrochloride oral solution with a density of 1.003 kg / L.
[0044] The content of the tropisetron hydrochloride oral solution obtained in Examples 1 to 4 and Comparative Example 1 was tested, the appearance was recorded, and accelerated 6-month, long-term 6-month, long-term 12-month and long-term 24-month tests were performed, respectively. The results are shown in Table 1, wherein the accelerated test conditions are: 40° C., RH75%; the long-term test conditions are: 25° C., RH60%.
[0045] Table 1
[0046]
[0047] The above description is only a preferred specific implementation manner of the present invention, but the protection scope of the present invention is not limited thereto. Any technician familiar with the technical field can make equivalent replacements or changes according to the technical scheme and inventive concept of the present invention within the technical scope disclosed by the present invention, which should be covered by the protection scope of the present invention.
Claims
1. A pharmaceutical composition, characterized in that include: Tropisetron hydrochloride; and terpene glycosides.
2. The pharmaceutical composition according to claim 1, characterized in that The terpene glycosides are selected from one or more tetracyclic diterpene glycosides.
3. The pharmaceutical composition according to claim 2, characterized in that The terpene glycosides are selected from one or more of mogroside, paeoniflorin and stevioside.
4. The pharmaceutical composition according to claim 1, characterized in that The mass ratio of tropisetron hydrochloride to terpene glycosides is 1:(0.8-1.2).
5. The pharmaceutical composition according to claim 1, characterized in that Also includes citric acid and sodium citrate; The mass ratio of tropisetron hydrochloride, terpene glycosides, citric acid and sodium citrate is 1:(0.8-1.2):0.4:0.
7.
6. A pharmaceutical preparation, characterized in that It comprises the pharmaceutical composition according to any one of claims 1 to 5 and a pharmaceutically acceptable additive.
7. The pharmaceutical preparation according to claim 6, characterized in that The dosage form of the pharmaceutical preparation is oral solution, injection or tablet.
8. The pharmaceutical preparation according to claim 6, characterized in that The liquid density of the pharmaceutical preparation is 1.002-1.009 kg / L.
9. A method for preparing tropisetron hydrochloride oral solution, characterized in that: The following steps are involved: The pharmaceutical composition according to any one of claims 1 to 5 is mixed in a solvent, and the pH value is adjusted to 4.3 to 5.7 to obtain a tropisetron hydrochloride oral solution.
10. The method for preparing the tropisetron hydrochloride oral solution according to claim 9, characterized in that: The solvent is selected from at least one of glycerol and water.
